(NYSEMKT: CLDI) Calidi Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.04%.
Calidi Biotherapeutics's earnings in 2026 is -$25,010,000.On average, 3 Wall Street analysts forecast CLDI's earnings for 2026 to be -$109,678,443, with the lowest CLDI earnings forecast at -$105,375,813, and the highest CLDI earnings forecast at -$112,903,484. On average, 3 Wall Street analysts forecast CLDI's earnings for 2027 to be -$94,549,716, with the lowest CLDI earnings forecast at -$90,841,884, and the highest CLDI earnings forecast at -$97,330,590.
In 2028, CLDI is forecast to generate -$92,185,973 in earnings, with the lowest earnings forecast at -$88,570,837 and the highest earnings forecast at -$94,897,325.